Compare Oruka Therapeutics Inc. Common Stock (ORKA) vs Viavi Solutions Inc. Common Stock (VIAV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oruka Therapeutics Inc. Common Stock vs Viavi Solutions Inc. Common Stock — how do they compare? Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.08B), while Viavi Solutions Inc. Common Stock trades at $36.98 (market cap $9.48B). The key difference: Viavi Solutions Inc. Common Stock is the larger of the two by market cap, and Oruka Therapeutics Inc. Common Stock is more actively traded (685,276 versus 4,534,703). Which is the better fit depends on your goals — on Pluang, investors hold Oruka Therapeutics Inc. Common Stock for 0 Days and Viavi Solutions Inc. Common Stock for 6 Days on average.
| ORKA | VIAV | |
|---|---|---|
Market Cap | $5.08B | $9.48B |
Volume | 685,276 | 4,534,703 |
Sector | Health | Technology |
52-Week High | $113.08 | $55.33 |
52-Week Low | $26.19 | $13.01 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $4.21B | $9.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VIAVI Solutions (VIAV) trades at $41.28, down 1.13% on the day, with mixed technical signals showing bearish overall momentum but bullish moving averages. The company demonstrates strong revenue growth with fiscal 2026 revenue reaching $1.52B (up 40% YoY) and has beaten earnings estimates for three consecutive quarters. Recent developments include a U.S. Army contract for defense testing and expanded partnerships in network validation, positioning VIAV for growth in AI data center and defense markets.
While analyst consensus remains strongly bullish with a $60.25 price target (78.95% buy ratings), investors face risks from negative net income margins (-2%) and elevated valuation metrics (P/S 6.24, EV/EBITDA 60.68). The stock's outlook depends on continued execution in high-growth segments and margin improvement to justify current valuations amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →About Viavi Solutions Inc. Common Stock
Viavi Solutions provides network testing, monitoring, and optical technologies. Its products help communications providers, equipment makers, and enterprises build and maintain networks.
Read more on VIAV →
